Expert Interview
A Second Look: Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Ticker(s): IMVT, ROIVInstitution: Fondazione IRCCS Cà Granda
- Founder and Head of Graves' Orbitopathy Center at Fondazione IRCCS Cà Granda, University of Milan
- Treats 500 patients per year with Graves’ Disease
- Research interest in immunotherapy and clinical studies with rituximab, the anti-BAFF belimumab, the anti-IGF-1 receptor antibody teprotumumab, and the anti-Il-6 receptor antibody tocilizumab in Graves' orbitopathy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
